PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9351902-2	1997	In the first example, deconvolution of the portal blood profiles of etretinate (ET, a synthetic retinoid) indicated that there was significant gut-wall conversion of ET to acitretin (ETA, the primary metabolite of ET) during a 60-min intestinal perfusion of ET.	Etretinate	166-168	endothelin receptor type A	Homo sapiens	183-186
22033771-10	2012	CONCLUSION: At later developmental stages, the expression levels of SP, VIP, and c-kit reduced in the circular muscle layer of the rectum in mice with etretinate-induced ARMs.	Etretinate	151-161	tachykinin 1	Mus musculus	68-70
22033771-10	2012	CONCLUSION: At later developmental stages, the expression levels of SP, VIP, and c-kit reduced in the circular muscle layer of the rectum in mice with etretinate-induced ARMs.	Etretinate	151-161	vasoactive intestinal polypeptide	Mus musculus	72-75
22033771-10	2012	CONCLUSION: At later developmental stages, the expression levels of SP, VIP, and c-kit reduced in the circular muscle layer of the rectum in mice with etretinate-induced ARMs.	Etretinate	151-161	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	81-86
16433796-15	2006	In two children, the elevated pretreatment ALP levels increased further after commencing etretinate but returned to normal in adulthood while treatment continued.	Etretinate	89-99	alkaline phosphatase, placental	Homo sapiens	43-46
10427950-2	1999	We studied the toxicity and the potential efficacy of an association of high dose etretinate and Interferon-alpha (IFN-alpha) in squamous cell carcinomas of the lung, head and neck, the esophagus, cervix and the penis, as well as in transitional carcinomas of the bladder.	Etretinate	82-92	interferon alpha 1	Homo sapiens	115-124
22929532-0	2012	Primary cutaneous CD30+ lymphoproliferative disorder successfully treated by etretinate.	Etretinate	77-87	TNF receptor superfamily member 8	Homo sapiens	18-22
16130505-4	2005	We examined changes in dermal thickness and appearance of skin disorders in five months old MRL/lpr mice by oral treatment with etretinate, a retinoic acid derivative.	Etretinate	128-138	Fas (TNF receptor superfamily member 6)	Mus musculus	96-99
16130505-5	2005	Etretinate treated MRL/lpr mice did not have skin lesions or dermatopathological characteristics including an increase in cells infiltrating the dermis.	Etretinate	0-10	Fas (TNF receptor superfamily member 6)	Mus musculus	23-26
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	65-75	Fas (TNF receptor superfamily member 6)	Mus musculus	149-152
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	65-75	Fas (TNF receptor superfamily member 6)	Mus musculus	149-152
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	65-75	Fas (TNF receptor superfamily member 6)	Mus musculus	292-303
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	163-173	Fas (TNF receptor superfamily member 6)	Mus musculus	149-152
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	163-173	Fas (TNF receptor superfamily member 6)	Mus musculus	149-152
16130505-6	2005	The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen.	Etretinate	163-173	Fas (TNF receptor superfamily member 6)	Mus musculus	292-303
11176940-0	2001	Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.	Etretinate	0-10	interferon beta 1	Homo sapiens	20-35
11176940-14	2001	CONCLUSIONS: Etretinate treatment at a dose of 10 mg twice or three times daily augments suppressor cell function in patients with MS receiving interferon beta-1b.	Etretinate	13-23	interferon beta 1	Homo sapiens	144-159
10871075-0	2000	Lamellar ichthyosis: response to etretinate with transglutaminase 1 recovery.	Etretinate	33-43	transglutaminase 1	Homo sapiens	49-67
9351902-2	1997	In the first example, deconvolution of the portal blood profiles of etretinate (ET, a synthetic retinoid) indicated that there was significant gut-wall conversion of ET to acitretin (ETA, the primary metabolite of ET) during a 60-min intestinal perfusion of ET.	Etretinate	166-168	endothelin receptor type A	Homo sapiens	183-186
9351902-2	1997	In the first example, deconvolution of the portal blood profiles of etretinate (ET, a synthetic retinoid) indicated that there was significant gut-wall conversion of ET to acitretin (ETA, the primary metabolite of ET) during a 60-min intestinal perfusion of ET.	Etretinate	166-168	endothelin receptor type A	Homo sapiens	183-186
7606369-2	1995	OBJECTIVE: To evaluate the efficacy of etretinate as an adjunctive therapy for recalcitrant palmar and plantar hyperkeratosis in erythrodermic CTCL patients undergoing photopheresis.	Etretinate	39-49	TSPY like 2	Homo sapiens	143-147
9204056-4	1997	OBJECTIVE: Our purpose was to investigate the immunohistochemical expression of p53 protein in premalignant and malignant cutaneous lesions in kidney transplant recipients and the effect of low-dose etretinate on p53 expression.	Etretinate	199-209	tumor protein p53	Homo sapiens	213-216
7619051-8	1995	Two of these other retinoids, 13-cis-retinoic acid and Ro13-7410, inhibited EGF binding the most (35-46%, P < 0.001); several others (etarotene, Ro40-8757 and etretinate) were less effective (7-16%), but significantly decreased EGF binding (P < 0.05), and two retinoids (Ro15-0778 and acitretin) showed no significant effect on EGF binding.	Etretinate	162-172	epidermal growth factor	Homo sapiens	76-79
8915849-11	1996	Surprisingly the inflammation-associated proteins HLA-DR and ICAM-1 were no longer produced by epidermal keratinocytes following etretinate treatment, and CD3+, CD8+, and CD25+ T-lymphocyte subsets were reduced by 50-65% in lesional tissue (p < 0.01).	Etretinate	129-139	intercellular adhesion molecule 1	Homo sapiens	61-67
7606369-3	1995	METHODS: Five patients with erythrodermic CTCL and recalcitrant palmar and plantar hyperkeratosis were given etretinate (0.8 mg/kg per day) while undergoing photopheresis therapy.	Etretinate	109-119	TSPY like 2	Homo sapiens	42-46
7606369-5	1995	CONCLUSION: Etretinate is a safe and effective adjunctive treatment for recalcitrant palmar and plantar hyperkeratosis in erythrodermic CTCL patients undergoing photopheresis.	Etretinate	12-22	TSPY like 2	Homo sapiens	136-140
1401309-6	1992	Etretinate treatment resulted in a substantial decrease in tumor necrosis factor-alpha levels, whereas an unpredictable increase was found during the late phase of cyclosporine treatment.	Etretinate	0-10	tumor necrosis factor	Homo sapiens	59-86
7775379-1	1995	Effects of retinoid derivatives (retinol, retinal, retinoic acid, and etretinate) on elastin expression and cell proliferation in chick embryonic vascular smooth muscle cells were compared.	Etretinate	70-80	elastin	Gallus gallus	85-92
7999596-0	1994	Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis.	Etretinate	0-10	collagen type I alpha 2 chain	Homo sapiens	54-72
7798436-3	1994	After oral etretinate with a dosage of 50 mg daily was combined with INF-alpha, marked clinical improvement was seen in skin lesions with minor side effects.	Etretinate	11-21	interferon alpha 17	Homo sapiens	69-78
8149476-7	1994	The retinoic acid analogue RO-109359 which, unlike RA, does not have tumor promoting activity per se, inhibited the TPA-induced increase in epidermal GM-CSF mRNA levels.	Etretinate	27-36	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	150-156
7962965-0	1994	Effects of etretinate on keratinocyte proliferation and secretion of interleukin-1 alpha (IL-1 alpha) and IL-8.	Etretinate	11-21	interleukin 1 alpha	Homo sapiens	69-88
7962965-0	1994	Effects of etretinate on keratinocyte proliferation and secretion of interleukin-1 alpha (IL-1 alpha) and IL-8.	Etretinate	11-21	interleukin 1 alpha	Homo sapiens	90-100
7962965-5	1994	Etretinate was shown to have an effect on either IL-1 alpha or IL-8 secretion in unstimulated NHKs.	Etretinate	0-10	interleukin 1 alpha	Homo sapiens	49-59
7962965-5	1994	Etretinate was shown to have an effect on either IL-1 alpha or IL-8 secretion in unstimulated NHKs.	Etretinate	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	63-67
7962965-8	1994	Stimulation of NHKs with PMA significantly enhanced IL-1 alpha and IL-8 secretion, and these effects were inhibited by etretinate.	Etretinate	119-129	interleukin 1 alpha	Homo sapiens	52-62
7962965-8	1994	Stimulation of NHKs with PMA significantly enhanced IL-1 alpha and IL-8 secretion, and these effects were inhibited by etretinate.	Etretinate	119-129	C-X-C motif chemokine ligand 8	Homo sapiens	67-71
8072039-6	1994	These results indicated that treatment with Etretinate during the gestation period might induce a decrease in the number of receptors of GH and IGF-I or other changes, such as a poor-response in target tissues due to a down-regulation, with an increase of serum GH and IGF-I levels.	Etretinate	44-54	insulin-like growth factor 1	Rattus norvegicus	144-149
8072039-6	1994	These results indicated that treatment with Etretinate during the gestation period might induce a decrease in the number of receptors of GH and IGF-I or other changes, such as a poor-response in target tissues due to a down-regulation, with an increase of serum GH and IGF-I levels.	Etretinate	44-54	insulin-like growth factor 1	Rattus norvegicus	269-274
1836350-1	1991	Two patients with ichthyosis bullosa of Siemens (IBS) and one patient with bullous ichthyosiform erythroderma of Brocq (BIE) were treated with etretinate.	Etretinate	143-153	keratin 10	Homo sapiens	120-123
2539770-4	1989	The increase in CRBP concentration was more pronounced in retinyl palmitate-treated tumours than in tumour tissue from etretinate- (an aromatic retinoid) treated mice and controls, suggesting that CRBP synthesis is under the influence of its ligand.	Etretinate	119-129	retinol binding protein 1, cellular	Mus musculus	16-20
1979727-0	1990	Etretinate suppresses ICAM-1 expression by lesional keratinocytes in healing cutaneous lichen planus.	Etretinate	0-10	intercellular adhesion molecule 1	Homo sapiens	22-28
2573489-4	1989	After a dose of ET, its two metabolites, ETA and c-ETA, were also detectable in the plasma.	Etretinate	16-18	endothelin receptor type A	Canis lupus familiaris	41-44
2573489-4	1989	After a dose of ET, its two metabolites, ETA and c-ETA, were also detectable in the plasma.	Etretinate	16-18	endothelin receptor type A	Canis lupus familiaris	51-54
2585775-0	1989	[A case of psoriasis vulgaris whose lipoprotein lipase activity decreased during treatment with etretinate].	Etretinate	96-106	lipoprotein lipase	Homo sapiens	36-54
2585775-5	1989	However, in the case of one 35-year old man, LPL activity markedly decreased on day 28 after the administration of etretinate and was restored when the administration was suspended.	Etretinate	115-125	lipoprotein lipase	Homo sapiens	45-48
2585775-7	1989	Therefore, it appeared that the decrease of LPL activity in this case was mainly due to the administration of etretinate.	Etretinate	110-120	lipoprotein lipase	Homo sapiens	44-47
3049737-0	1988	The effect of etretinate on plasma fibronectin in patients with vulgar psoriasis.	Etretinate	14-24	fibronectin 1	Homo sapiens	35-46
3954950-4	1986	In the ichthyotics studied the levels of G6PDH and SDH activity were significantly lowered following etretinate therapy, to levels similar to those demonstrated in normal subjects.	Etretinate	101-111	glucose-6-phosphate dehydrogenase	Homo sapiens	41-46
2967472-7	1988	In patients receiving etretinate the terminal disposition or elimination half-lives for cisetretin (t 1/2 lambda 3 15.9 +/- 9.9 days) were longer than for the metabolite etretin and exhibit a pronounced interindividual variation from 4.25 to 22.8 days.	Etretinate	22-32	interleukin 1 receptor like 1	Homo sapiens	100-103
2445144-2	1987	Aberrant expression of cytokeratin PKK2 (Labsystems, Helsinki, Finland) in lesional EKV stratum corneum was observed; this feature disappeared after Etretinate therapy.	Etretinate	149-159	ankyrin repeat and kinase domain containing 1	Homo sapiens	35-39
2448994-5	1987	Sera from two patients treated with a combination of etretinate and colchicine contained extremely low levels of IL-2 inhibitory activity.	Etretinate	53-63	interleukin 2	Homo sapiens	113-117
3747550-4	1986	The inhibition by all trans-retinoic acid of ornithine decarboxylase induced by cellotape stripping was dose dependent as was found to be the case for arotinoid, retinol, Ro-10-1670, motretinid, 13-cis-retinoic acid, etretinate, and vitamin A.	Etretinate	217-227	ornithine decarboxylase 1	Rattus norvegicus	45-68
3954950-4	1986	In the ichthyotics studied the levels of G6PDH and SDH activity were significantly lowered following etretinate therapy, to levels similar to those demonstrated in normal subjects.	Etretinate	101-111	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	51-54
3954950-5	1986	In contrast, the activity of NSE was increased in the ichthyotics after etretinate therapy.	Etretinate	72-82	enolase 2	Homo sapiens	29-32
7068977-0	1982	Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase.	Etretinate	0-10	ornithine decarboxylase 1	Homo sapiens	54-77
7068977-3	1982	The effect of etretinate has been studied on ODC activity in involved and uninvolved psoriasis skin.	Etretinate	14-24	ornithine decarboxylase 1	Homo sapiens	45-48
7068977-5	1982	Etretinate treatment significantly reduced ODC activity in both involved and uninvolved skin in psoriatics to a similar level of activity before any improvement in clinical appearance was noted.	Etretinate	0-10	ornithine decarboxylase 1	Homo sapiens	43-46
6183879-0	1982	The effect of etretinate on fibronectin in psoriatic skin.	Etretinate	14-24	fibronectin 1	Homo sapiens	28-39
6183879-1	1982	The distribution of fibronectin in psoriatic skin was studied in 6 patients during treatment with oral etretinate using indirect immunofluorescence technique.	Etretinate	103-113	fibronectin 1	Homo sapiens	20-31